# [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

> **NCT05870579** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** [68Ga]Ga-NeoB
- **DRUG:** [177Lu]Lu-NeoB
- **DRUG:** Ribociclib
- **DRUG:** Fulvestrant
- **OTHER:** Goserelin

## Key facts

- **NCT ID:** NCT05870579
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2026-12-30
- **Final completion:** 2032-01-26
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870579, "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05870579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*